We’re a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we’re taking could succeed in defeating herpes by inducing antibodies that mediate the killing of infected cells. We’re strongly committed to this fight, and so far our work has been supported with unprecedented data in multiple preclinical models.